1. Home
  2. EIM vs OBIO Comparison

EIM vs OBIO Comparison

Compare EIM & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eaton Vance Municipal Bond

EIM

Eaton Vance Municipal Bond

N/A

Current Price

$8.76

Market Cap

503.5M

Sector

Finance

ML Signal

N/A

OBIO

Orchestra BioMed Holdings Inc.

N/A

Current Price

$6.57

Market Cap

473.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EIM
OBIO
Founded
N/A
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
503.5M
473.0M
IPO Year
2002
2020

Fundamental Metrics

Financial Performance
Metric
EIM
OBIO
Price
$8.76
$6.57
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
★ $13.29
AVG Volume (30 Days)
339.1K
★ 502.8K
Earning Date
01-01-0001
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 33.13
EPS
★ N/A
N/A
Revenue
N/A
★ $33,482,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$39.94
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 1169.22
52 Week Low
$8.64
$3.46
52 Week High
$10.05
$7.83

Technical Indicators

Market Signals
Indicator
EIM
OBIO
Relative Strength Index (RSI) 34.01 54.17
Support Level $8.64 $5.39
Resistance Level $10.01 N/A
Average True Range (ATR) 0.12 0.60
MACD -0.05 0.10
Stochastic Oscillator 4.17 52.84

Price Performance

Historical Comparison
EIM
OBIO

About EIM Eaton Vance Municipal Bond

Eaton Vance Municipal Bond Fund is a non-diversified closed-end management investment company. It consists of Municipal bond fund, California municipal bond fund, and New York municipal bond fund. The company's investment objective is to provide current income exempt from regular federal income tax, alternative minimum tax, and taxes in specified states. Its investment plan is to invest in higher quality bonds.

About OBIO Orchestra BioMed Holdings Inc.

Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.

Share on Social Networks: